Carmelina
Boehringer Ingelheim and Lilly present full results of Trajenta ®’s CARMELINA® cardiovascular outcome trial Trajenta ® demonstrated a similar long-term cardiovascular and kidney safety profile compared to placebo in adults with type 2 diabetes1 The results of CARMELINA ® were presented at the 54th EASD Annual Meeting today
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Cardiology | Cardiovascular | Diabetes Type 2 | Endocrinology | Heart | Research | Urology & Nephrology